Effect of Empagliflozin in prevention of kidney stone parameters
Phase 3
Completed
- Conditions
- urolithiasis.Calculus of kidney with calculus of ureterN20.2
- Registration Number
- IRCT20211203053261N2
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 138
Inclusion Criteria
Patients in the age range of 18 to 65 years
Patients with a history of kidney stones in the last 5 years
Exclusion Criteria
Diabetic patients
Taking antidiabetic drugs
Taking diuretic drugs
Chronic kidney disease patients
pregnancy
Patients with genital infections
Patients with urinary infections
breastfeeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does empagliflozin use to prevent urinal parameter increases in urolithiasis patients?
How does empagliflozin compare to standard-of-care treatments in preventing kidney stone formation in IRCT20211203053261N2?
Which biomarkers are associated with empagliflozin's effectiveness in managing N20.2 kidney and ureteral calculus cases?
What are the potential adverse events of empagliflozin in urolithiasis patients and how can they be managed?
Are there any combination therapies or competitor drugs that enhance empagliflozin's efficacy in preventing urolithiasis?